Close Menu
Home » FDA Approves AstraZeneca's Lynparza, Myriad Genetics' CDx for BRCA-Positive Pancreatic Cancer

FDA Approves AstraZeneca's Lynparza, Myriad Genetics' CDx for BRCA-Positive Pancreatic Cancer

Dec 30, 2019
|
staff reporter

NEW YORK – The US Food and Drug Administration expanded the indication for AstraZeneca and Merck's olaparib (Lynparza) as a maintenance treatment for certain metastatic pancreatic cancer patients identified with the help of a companion diagnostic, the two drugmakers announced on Monday.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Test of Antibodies

According to NPR, an antibody-based test could identify people who were exposed to SARS-CoV-2 and either didn't develop symptoms or were misdiagnosed.

New York Rats Through and Through

A sequencing analysis of New York City rats indicates they have adapted to the urban environment there, according to a recent preprint.

Powerhouse of the Cell, Lost

Ars Technica reports that a multicellular eukaryotic parasite has lost its mitochondria.

Science Papers Discuss AI in Drug Discovery, Find Two Red Panda Species

In Science this week: perspective piece says AI can accelerate drug discovery by using genomic and chemical data, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. Congressional Caucus Working to Raise Personalized Medicine Awareness Among Legislators

    Premium

  2. Co-Diagnostics SARS-CoV-2 Assay Garners CE Mark

  3. Luminex Submits Verigene II Respiratory Assay for FDA Clearance

  4. Asuragen Fragile X Diagnostic Test Gets FDA Authorization

  5. Streck Antibiotic Resistance Kits Receive CE Mark

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.